OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Release Date
2018
(1)
2015
(1)
2013
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
Not available
S-EPMC5795709
|
biostudies-literature
Cite
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Not available
S-EPMC6075852
|
biostudies-literature
Cite
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Not available
S-EPMC4878048
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
